Page 22 - Cipla
Cipla gains post June quarter results
The stock was up 5% at Rs 540 on the NSE, as compared to 0.57% fall in the Nifty 50 index at 12:49 pm.
 "Cipla gains post June quarter results")
Cipla's net profit dips 44%, announces new CEO
Overall revenue of Cipla falls 6%; international business drops 14%
Cipla first quarter profit lags estimates; names new CEO
Cipla's April-June net profit was 3.65 billion rupees, compared with 6.49 billion rupees a year earlier
 "Cipla first quarter profit lags estimates; names new CEO")
Cipla appoints Kedar Upadhye as Global CFO
Earlier, he has worked with Pepsi India and Thermax Group
 "Cipla appoints Kedar Upadhye as Global CFO")
Cipla told to deposit Rs 175 crore in drug overcharging case
The case pertains to 2003 when Cipla received a demand notice from the National Pharmaceutical Pricing Authority for alleged overcharging of drugs covered under price cap
 "Cipla told to deposit Rs 175 crore in drug overcharging case")
Cipla to set up biotech plant in South Africa
Cipla Biotech, a subsidiary of the company, will construct the plant at a special economic zone in Durban and will commence production in 2018
Cipla: Short-term pain despite strong base
Cipla has missed analysts' expectation by 30 per cent at the EBITDA level for the year
 "Cipla: Short-term pain despite strong base")
Cipla hits 52-week low on disappointing Q4 results
The stock dipped 7% to Rs 460, also its 52-week low on the BSE.
 "Cipla hits 52-week low on disappointing Q4 results")
Cipla net profit declines 69% due to one-off expenses
Cipla's Ebitda also declined nearly 57% to Rs 219 crore
Cipla Q4 net drops 69% to Rs 81 cr
Consolidated total income from operations of the company stood at Rs 3,266.54 crore for the quarter under consideration
Cipla bets big on consumer health segment
Company aims to build five Rs 100 cr-plus brands and launch products from South African arm in domestic market
Cipla invests additional $ 3 million in US's Chase Pharmaceuticals
Company in May 2014 had invested $1.5 million to acquire 14.6% stake in Chase Pharmaceuticals
 "Cipla invests additional $ 3 million in US's Chase Pharmaceuticals")
Cipla transfers consumer healthcare business to subsidiary
Shares of Cipla today closed at Rs 517.50 per scrip on BSE, up 0.49% from the previous close
Cipla completes $550 million acquisition of 2 US generic drug companies
The acquisition of InvaGen and Exelan will boost Cipla's US business which currently accounts for 8% of its revenue
 "Cipla completes $550 million acquisition of 2 US generic drug companies")
